<DOC>
	<DOC>NCT00166322</DOC>
	<brief_summary>This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.</brief_summary>
	<brief_title>Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Clinical diagnosis of schizophrenia (currently unmedicated) Subjects at risk for the development of schizophrenia (prodromal symptoms) Healthy subjects Written informed consent Neurological or severe somatic disorders Women during pregnancy or lactation Occupational exposition to radiation &gt; 15mSv Medication known to interfere with IBZM Contraindications for the use of amphetamine challenge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>IBZM-SPECT</keyword>
	<keyword>Amphetamine Challenge</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>dopaminergic neurotransmission</keyword>
	<keyword>Persons at risk for the development of schizophrenia</keyword>
	<keyword>healthy subjects</keyword>
</DOC>